PMID- 31077529
OWN - NLM
STAT- MEDLINE
DCOM- 20200416
LR  - 20200416
IS  - 1520-7560 (Electronic)
IS  - 1520-7552 (Linking)
VI  - 35
IP  - 7
DP  - 2019 Oct
TI  - Improved skeletal muscle energy metabolism relates to the recovery of beta cell 
      function by intensive insulin therapy in drug naive type 2 diabetes.
PG  - e3177
LID - 10.1002/dmrr.3177 [doi]
AB  - AIMS: Diminished energy turnover of skeletal muscle is involved in the 
      development of type 2 diabetes. Intensive insulin therapy has been reported to 
      maintain glycaemic control in newly diagnosed type 2 diabetes, while the 
      underlying mechanism remains unclear. Herein, we aimed to characterize the 
      contribution of muscular mitochondrial oxidative phosphorylation (OxPhos) 
      activity to insulin-induced glycaemic control. MATERIALS AND METHODS: There were 
      21 drug naive patients with type 2 diabetes receiving continuous subcutaneous 
      insulin infusion for 7 days. Nine nondiabetics matched for age, body mass index, 
      and physical activity were recruited as controls. We applied (31) P magnetic 
      resonance spectroscopy to record in vivo muscular phosphocreatine (PCr) flux in 
      controls and diabetics before and after insulin therapy. The mitochondrial OxPhos 
      rate was calculated as DeltaPCr / Deltatime during the first 50 seconds after cessation 
      of exercise. RESULTS: In drug naive type 2 diabetes, muscular mitochondrial 
      OxPhos rate was restored after insulin therapy. Notably, this alteration was 
      positively associated with the improvements of 1,5-anhydroglucitol, a serum 
      marker for glucose control over the last 1 week, as well as homeostasis model 
      assessment of beta cell function and C-peptide/glucose ratio t(0) , two indices for 
      basal insulin secretion. Furthermore, patients with diabetes family history and 
      more severe glucotoxicity tend to achieve greater improvement in mitochondrial 
      function by insulin. CONCLUSIONS: This study provides evidence that intensive 
      insulin therapy facilitates muscular energy metabolism in drug naive type 2 
      diabetes. It correlates to the recovery of beta cell function, contributing to 
      insulin-induced glucose control.
CI  - (c) 2019 John Wiley & Sons, Ltd.
FAU - Tang, Wenjuan
AU  - Tang W
AD  - Department of Endocrinology, Drum Tower Hospital Affiliated to Nanjing University 
      Medical School, Nanjing, China.
FAU - Zhang, Bing
AU  - Zhang B
AD  - Department of Radiology, Drum Tower Hospital Affiliated to Nanjing University 
      Medical School, Nanjing, China.
FAU - Wang, Huiting
AU  - Wang H
AD  - Department of Radiology, Drum Tower Hospital Affiliated to Nanjing University 
      Medical School, Nanjing, China.
FAU - Li, Ming
AU  - Li M
AD  - Department of Radiology, Drum Tower Hospital Affiliated to Nanjing University 
      Medical School, Nanjing, China.
FAU - Wang, Hongdong
AU  - Wang H
AD  - Department of Endocrinology, Drum Tower Hospital Affiliated to Nanjing University 
      Medical School, Nanjing, China.
FAU - Liu, Fangcen
AU  - Liu F
AD  - Department of Endocrinology, Drum Tower Hospital Affiliated to Nanjing University 
      Medical School, Nanjing, China.
FAU - Zhu, Dalong
AU  - Zhu D
AD  - Department of Endocrinology, Drum Tower Hospital Affiliated to Nanjing University 
      Medical School, Nanjing, China.
FAU - Bi, Yan
AU  - Bi Y
AUID- ORCID: 0000-0003-3914-7854
AD  - Department of Endocrinology, Drum Tower Hospital Affiliated to Nanjing University 
      Medical School, Nanjing, China.
LA  - eng
SI  - ClinicalTrials.gov/NCT03710811
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20190527
PL  - England
TA  - Diabetes Metab Res Rev
JT  - Diabetes/metabolism research and reviews
JID - 100883450
RN  - 0 (Biomarkers)
RN  - 0 (Blood Glucose)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin)
SB  - IM
MH  - Adult
MH  - Biomarkers/analysis
MH  - Blood Glucose/analysis
MH  - Case-Control Studies
MH  - Diabetes Mellitus, Type 2/*drug therapy/metabolism/pathology
MH  - Energy Metabolism/*drug effects
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Insulin/*therapeutic use
MH  - Insulin Resistance
MH  - Insulin-Secreting Cells/drug effects/*physiology
MH  - Magnetic Resonance Spectroscopy
MH  - Male
MH  - Middle Aged
MH  - Muscle, Skeletal/drug effects/*metabolism
MH  - Prognosis
MH  - Recovery of Function
OTO - NOTNLM
OT  - drug naive type 2 diabetes
OT  - intensive insulin therapy
OT  - muscular energy metabolism
OT  - beta cell function
EDAT- 2019/05/12 06:00
MHDA- 2020/04/17 06:00
CRDT- 2019/05/12 06:00
PHST- 2018/11/16 00:00 [received]
PHST- 2019/04/15 00:00 [revised]
PHST- 2019/05/07 00:00 [accepted]
PHST- 2019/05/12 06:00 [pubmed]
PHST- 2020/04/17 06:00 [medline]
PHST- 2019/05/12 06:00 [entrez]
AID - 10.1002/dmrr.3177 [doi]
PST - ppublish
SO  - Diabetes Metab Res Rev. 2019 Oct;35(7):e3177. doi: 10.1002/dmrr.3177. Epub 2019 
      May 27.